

### Corporate Profile

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2017 were \$22.4 billion. For more information, visit [www.tevapharm.com](http://www.tevapharm.com).

### Primary IR Contact

Investor Relations  
**Phone:** (215) 591-3034  
**E-mail:**  
[TevaIRus@tevapharm.com](mailto:TevaIRus@tevapharm.com)

### Recent Headlines

May 23, 2018  
 Teva Confirms September PDUFA Date for Fremanezumab

May 15, 2018  
 Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association


May 03, 2018  
 Teva Reports First Quarter 2018 Financial Results

### Upcoming Events

There are currently no events scheduled.

### Analyst Estimates / Ratings

Mean Recommendation: **3.1**



Unable to fulfill request.

### SEC Filings

Filing Date	Form
05/11/18	4
05/03/18	10-Q
05/03/18	8-K
04/27/18	8-K

### Financial Reports

Date	
02/08/18	Fourth Quarter 2017 Earnings Press Release

### Presentations

Date	
05/03/18	Teva First Quarter Results 2018 Presentation

### Corporate Officers

#### Kåre Schultz

President and CEO

#### Gianfranco Nazzi

Executive Vice President, Growth Markets Commercial

#### Iris Beck-Codner

Executive Vice President, Global Brand & Communications

#### Dr. Carlo de Notaristefani

Executive Vice President, Global Operations

#### Richard Daniell

Executive Vice President, European Commercial

#### Brendan O'Grady

Executive Vice President, North America Commercial

#### Sven Dethlefs

Executive Vice President, Global Marketing & Portfolio

#### Mark Sabag

Group Executive Vice President, Human Resources

#### Dr. Hafrun Fridriksdottir

Executive Vice President, Global R&D

#### David M. Stark

Group Executive Vice President, Chief Legal Officer

#### Michael (Mike) McClellan

Executive Vice President, Chief Financial Officer

#### Nir Baron

Executive Vice President, Chief Internal Auditor